BIOMARIN PHARMACEUTICAL INC
BMRNNASDAQUS Equity
$252.91▲ $2.53 (+1.00%)
Simulated price1h—
24h▲ 1.0%
7d▲ 322.1%
14d▲ 312.2%
30d▲ 327.5%
1y▲ 345.0%
🏦Market Cap
$235.53B
Large Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
55
Weak
Trading Snapshot
- Day Range
- $251.82 – $254.10
- 52-Week Range
- —
- Volume
- $2.83B
- Avg Volume
- $3.59B
- Shares Outstanding
- —
- Next Earnings
- Oct 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $19.79B
- Last Q Revenue
- $5.08B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own BMRN
- ✓High-growth profile — revenue up +33.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 33% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$19.79B▲ +29.8% YoY
Gross Margin (TTM)
32.8%▲ +1.0% YoY
Operating Income (TTM)
$1.62B▲ +29.8% YoY
Free Cash Flow (TTM)
$3.68B▲ +29.8% YoY
About BIOMARIN PHARMACEUTICAL INC
A company profile for BIOMARIN PHARMACEUTICAL INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
55/100
Analyst Price Target
ⓘAverage Target
$289.84
▲ +14.6% Upside
High Target$313.23
Low Target$222.21
Based on 23 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
BIOMARIN PHARMACEUTICAL INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift BMRN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
BIOMARIN PHARMACEUTICAL INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.